Evidence map›Paper›PMID 33754148›Full record

ArticleThe Journal of clinical endocrinology and metabolism2021

Urinary Phthalate Biomarkers and Bone Mineral Density in Postmenopausal Women.

Katherine W Reeves, Gabriela Vieyra, Nydjie P Grimes, Jaymie Meliker, Rebecca D Jackson, Jean Wactawski-Wende, Robert Wallace, R Thomas Zoeller, Carol Bigelow, Susan E Hankinson and 3 more

Open access · bronzeAbstract readEvaluation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of clinical endocrinology and metabolism, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.

  1. Phthalates and bone mineral density: a systematic review.Environmental health : a global access science source · 2022
    Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Effects of Endocrine-Disrupting Chemicals on Bone Health.Endocrinology and metabolism (Seoul, Korea) · 2024
    Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 8 institutions in 1 country.

Katherine W ReevesDepartment of Biostatistics and Epidemiology, University of Massachusetts Amherst, Amherst, Massachusetts 01003, USA.ORCID 0000-0001-7856-981X
Gabriela VieyraDepartment of Biostatistics and Epidemiology, University of Massachusetts Amherst, Amherst, Massachusetts 01003, USA.
Nydjie P GrimesDepartment of Biostatistics and Epidemiology, University of Massachusetts Amherst, Amherst, Massachusetts 01003, USA.
Jaymie MelikerProgram in Public Health, Department of Family, Population, & Preventive Medicine, Stony Brook University, Stony Brook, New York 11794, USA.
Rebecca D JacksonDepartment of Medicine, Division of Endocrinology, Diabetes and Metabolism, The Ohio State University, Columbus, Ohio 43210, USA.
Jean Wactawski-WendeDepartment of Epidemiology and Environmental Health, School of Public Health and Health Professions, University at Buffalo, Buffalo, New York 14214, USA.ORCID 0000-0003-3096-9595
Robert WallaceDepartment of Epidemiology, College of Public Health, University of Iowa, Iowa City, Iowa 52242, USA.
R Thomas ZoellerDepartment of Biology, University of Massachusetts Amherst, Amherst, Massachusetts 01003, USA.
Carol BigelowDepartment of Biostatistics and Epidemiology, University of Massachusetts Amherst, Amherst, Massachusetts 01003, USA.
Susan E HankinsonDepartment of Biostatistics and Epidemiology, University of Massachusetts Amherst, Amherst, Massachusetts 01003, USA.
JoAnn E MansonDepartment of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02215, USA.
Jane A CauleyDepartment of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania 15213, USA.
Antonia M CalafatDivision of Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, Georgia 30341, USA.ORCID 0000-0002-9796-7482
University of Massachusetts Amherst · USBrigham and Women's Hospital · USCenters for Disease Control and Prevention · USStony Brook University · USThe Ohio State University · USUniversity at Buffalo, State University of New York · USUniversity of Iowa · USUniversity of Pittsburgh · US

Funding

Phthalate Metabolites and Breast Cancer Risk in the Women's Health InitiativeR01ES024731 · NIEHS · UNIVERSITY OF MASSACHUSETTS AMHERST · PI REEVES, KATHERINE WHITNEY · 2015 to 2017
$1.7M
NHLBI NIH HHS HHSN268201600001CNHLBI NIH HHS HHSN268201600002CNHLBI NIH HHS HHSN268201600003CNHLBI NIH HHS HHSN268201600004CNHLBI NIH HHS HHSN268201600018CNIEHS NIH HHS R01 ES024731
6 · The paper itself

Abstract

contextPhthalates are endocrine-disrupting chemicals that could disrupt normal physiologic function, triggering detrimental impacts on bone.

objectiveWe evaluated associations between urinary phthalate biomarkers and BMD in postmenopausal women participating in the prospective Women's Health Initiative (WHI).

methodsWe included WHI participants enrolled in the BMD substudy and selected for a nested case-control study of phthalates and breast cancer (N = 1255). We measured 13 phthalate biomarkers and creatinine in 2 to 3 urine samples per participant collected over 3 years, when all participants were cancer free. Total hip and femoral neck BMD were measured at baseline and year 3, concurrent with urine collection, via dual-energy x-ray absorptiometry. We fit multivariable generalized estimating equation models and linear mixed-effects models to estimate cross-sectional and longitudinal associations, respectively, with stratification on postmenopausal hormone therapy (HT) use.

resultsIn cross-sectional analyses, mono-3-carboxypropyl phthalate and the sum of di-isobutyl phthalate metabolites were inversely associated with total hip BMD among HT nonusers, but not among HT users. Longitudinal analyses showed greater declines in total hip BMD among HT nonusers and with highest concentrations of mono-3-carboxyoctyl phthalate (-1.80%; 95% CI, -2.81% to -0.78%) or monocarboxynonyl phthalate (-1.84%; 95% CI, -2.80% to -0.89%); similar associations were observed with femoral neck BMD. Among HT users, phthalate biomarkers were not associated with total hip or femoral neck BMD change.

conclusionCertain phthalate biomarkers are associated with greater percentage decreases in total hip and femoral neck BMD. These findings suggest that phthalate exposure may have clinically important effects on BMD, and potentially fracture risk.

Indexed as

Biological MonitoringBone DensityAbsorptiometry, PhotonAgedBiomarkersCase-Control StudiesCreatinineCross-Sectional StudiesEndocrine DisruptorsEnvironmental ExposureEstrogen Replacement TherapyFemaleFemur NeckHumansLongitudinal StudiesMiddle AgedBiomarkersCreatinineEndocrine Disruptorsphthalic acidPhthalic Acidsbiomarkersbone mineral densityphthalatepostmenopausalwomen

Identifiers

PMID33754148
PMCPMC8266434
OpenAlexW3138838387

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.